Global Plasma Protease C1-inhibitor Treatment Market to Reach $16.1 Billion by 2030
The global market for Plasma Protease C1-inhibitor Treatment estimated at US$4.5 Billion in the year 2023, is expected to reach US$16.1 Billion by 2030, growing at a CAGR of 19.9% over the analysis period 2023-2030. C1-Inhibitor Drug Class, one of the segments analyzed in the report, is expected to record a 18.2% CAGR and reach US$7.9 Billion by the end of the analysis period. Growth in the Kallikrein Inhibitor (Kalbitor) Drug Class segment is estimated at 20% CAGR for the next 7-year period.
The U.S. Market is Estimated at $1.4 Billion, While China is Forecast to Grow at 19.1% CAGR
The Plasma Protease C1-inhibitor Treatment market in the U.S. is estimated at US$1.4 Billion in the year 2023. China, the world`s second largest economy, is forecast to reach a projected market size of US$2.7 Billion by the year 2030 trailing a CAGR of 19.1% over the analysis period 2023 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 17.6% and 17.2% respectively over the 2023-2030 period. Within Europe, Germany is forecast to grow at approximately 14.7% CAGR.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook